Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed ...

26 October 2026 · By · Wire by Fusion42

Published

26 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at insilico.com →

◆ Verified

Fusion42 · 26 October 2026 · Fusion42 review

Insilico Medicine announced promising Phase 1 data for ISM6331, a generative AI-designed oral pan-TEAD inhibitor, showing a 40% objective response rate at 130 mg in heavily pretreated mesothelioma patients with manageable safety. The drug has FDA Orphan Drug and Fast Track designations and plans to proceed to a Phase 2a randomized study.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You need to update your oncology pipeline thinking on AI-designed candidates showing clinical promise in tough cancers. Insilico’s success shifts focus to generative AI as a direct path to new cancer therapies ready for dose optimisation now.

◆ Coverage

1 source · 26 Oct 2026

◆ Related on Wire

◆ Topics

Biotechgenerative-aioncology-drugphase-1-resultstead-inhibitormesothelioma